Affinity Asset Advisors LLC Sells 100,000 Shares of Establishment Labs Holdings Inc. $ESTA

Affinity Asset Advisors LLC decreased its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 50.0% in the 1st quarter, HoldingsChannel reports. The firm owned 100,000 shares of the company’s stock after selling 100,000 shares during the period. Affinity Asset Advisors LLC’s holdings in Establishment Labs were worth $5,678,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. grew its holdings in Establishment Labs by 59.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 115,876 shares of the company’s stock valued at $8,445,000 after buying an additional 43,164 shares in the last quarter. Simplify Asset Management Inc. boosted its position in shares of Establishment Labs by 92.1% in the fourth quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock valued at $5,313,000 after acquiring an additional 34,946 shares during the period. SG Americas Securities LLC boosted its position in shares of Establishment Labs by 134.3% in the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock valued at $2,154,000 after acquiring an additional 21,742 shares during the period. AlTi Global Inc. acquired a new position in shares of Establishment Labs in the first quarter valued at about $842,000. Finally, Cannon Global Investment Management LLC acquired a new position in shares of Establishment Labs in the first quarter valued at about $738,000. 72.91% of the stock is owned by institutional investors.

Insider Buying and Selling at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 182,180 shares of company stock valued at $13,369,722 over the last ninety days. Corporate insiders own 9.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. Mizuho lifted their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. BTIG Research reiterated a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Finally, Citigroup increased their price target on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $90.43.

Establishment Labs Trading Up 1.3%

Shares of NASDAQ ESTA opened at $92.32 on Friday. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. Establishment Labs Holdings Inc. has a 52-week low of $33.35 and a 52-week high of $96.99. The stock has a market cap of $2.72 billion, a P/E ratio of -61.96 and a beta of 1.06. The firm has a 50 day moving average price of $82.58 and a two-hundred day moving average price of $72.72.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm’s revenue for the quarter was up 44.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.70) earnings per share. As a group, equities analysts forecast that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.